Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
05 sept. 2023 07h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
Monopar Provides Encouraging Camsirubicin Clinical Data Update
08 août 2023 07h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for...
Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore
11 juil. 2023 07h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., July 11, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, today...
Monopar to Participate in the Radiopharma Forum by the Lake 2023
21 juin 2023 07h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., June 21, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update
01 juin 2023 07h00 HE
|
Monopar Therapeutics Inc.
Patient in 520 mg/m2 cohort, previously unresectable, experienced tumor shrinkage and had tumor resected following camsirubicin treatment 3 of 3 patients in the 520 mg/m2 cohort achieved stable...
Monopar to Present at the 35th Annual Roth Conference
07 mars 2023 07h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., March 07, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin
14 févr. 2023 07h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT
26 janv. 2023 07h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2
18 janv. 2023 07h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration
12 déc. 2022 07h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...